AstraZeneca Launches Two Nutrition Websites

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 6
Volume 10
Issue 6

WILMINGTON, Del-AstraZeneca Pharmaceuticals has announced the launch of two new websites designed to make nutritional product information and nutritional news more readily available to US health care professionals.

WILMINGTON, Del—AstraZeneca Pharmaceuticals has announced the launch of two new websites designed to make nutritional product information and nutritional news more readily available to US health care professionals.

For the total parenteral nutrition professional, www.TPNpro.com contains articles, news feeds from Reuters News Service, links, tables and a calculator, daily facts from RealAge, and access to continuing education credits.

For information on AstraZeneca’s M.V.I.-12 (multivitamins for infusion) and M.V.I. Pediatric (multivitamins for infusion), including ordering information and patient brochures, professionals can visit www.MVI-us.com. 

Articles in this issue
ACS and NCCN Issue Cancer Pain Management Guidelines for Patients
Xeloda Approved for Metastatic Colorectal Cancer
Walking Improves Fatigue, Sleep in Breast Cancer Patients
Bezwoda 1985 Breast Cancer Transplant Study Fraudulent
Severity of Hot Flashes Worse in Breast Cancer Survivors
Tamoxifen Prevents BRCA2, But Not BRCA1, Breast Cancer
High TIMP-1 Levels May Promote Prostate Cancer Growth
Barriers to Colorectal Cancer Screening Among Minorities
Epoetin Reduces Need for Red Blood Cell Transfusions
French Researchers Discover How HIV Makes First Contact
‘Virtual Supercomputer’ Program for Cancer Drug Discovery
Agent Orange Linked to AML in Offspring
Turkish Towns Provide Genetic Link to Malignant Mesothelioma
President Allows Implementation of Patient Privacy Rule
Gleevec Is Approved for Chronic Myelogenous Leukemia
Recent Videos
Retrospective and real-world registry studies may be necessary to guide clinical decision-making for rarer lymphomas with insufficient prospective data.
Extravasation results in exposing healthy tissue to radiation, which can be highly dosed depending on the isotope used for treatment.
4 experts in this video
2 experts in this video
2 experts in this video
4 experts in this video
Ongoing studies seek to evaluate immunotherapy in earlier lines of therapy for patients with early-stage Hodgkin lymphoma.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
Related Content
92 Near-Infrared Fluorescence Imaging With Indocyanine Green vs Isosulfan Blue for Sentinel Lymph Node Mapping: Comparative Cost Analysis in Early-Stage Breast Cancer

92 Near-Infrared Fluorescence Imaging With Indocyanine Green vs Isosulfan Blue for Sentinel Lymph Node Mapping: Comparative Cost Analysis in Early-Stage Breast Cancer

Michelle Sosa;Deirdre McNicholas;Arbelina Bebla;Seth Emont;Zhun Cao;Manu Tyagi;Craig Lipkin;Sommer Gunia
April 19th 2025
Article
Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Cristiane Decat Bergerot, PhD
April 14th 2025
Podcast

Integrating psychosocial care into cancer care allows patients to receive emotional support, counseling, and coping strategies to help navigate treatment.

Multivariate analysis showed consolidative thoracic radiotherapy improved OS/PFS vs control patients with ES-SCLC, with respective HRs of 0.53 and 0.90.

Consolidative Thoracic Radiotherapy Improves Survival in ES-SCLC

Roman Fabbricatore
April 18th 2025
Article

Multivariate analysis showed consolidative thoracic radiotherapy improved OS/PFS vs control patients with ES-SCLC, with respective HRs of 0.53 and 0.90.

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Elevating the Quality of Cancer Care via Cross-Department Collaboration

Rachit Kumar, MD;Michael J. Pishvaian, MD, PhD;Nina D. Wagner-Johnston, MD;Valerie Lee, MD;Armine K. Smith, MD;Pouneh Razavi, MD;Curtiland Deville Jr., MD
April 7th 2025
Podcast

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Patients with painful lesions who did not undergo treatment with opioids or reirradiation generally had better outcomes than those who did.

Classification System May Identify QOL Benefit with Palliative Radiotherapy

Roman Fabbricatore
April 18th 2025
Article

Patients with painful lesions who did not undergo treatment with opioids or reirradiation generally had better outcomes than those who did.

UK’s MHRA Approves Belantamab Mafodotin/Chemo in Myeloma Indications

UK’s MHRA Approves Belantamab Mafodotin/Chemo in Myeloma Indications

Tim Cortese
April 18th 2025
Article

Results from the DREAMM-7 and DREAMM-8 trials support the approval of belantamab mafodotin with chemotherapy in relapsed/refractory multiple myeloma.